Barricade Therapeutics
Angel
Clinical-stage oncology company developing first-in-class oral therapies for genetically driven cancers
Clinical-stage oncology company developing first-in-class oral therapies for genetically driven cancers
Bull case: Non-dilutive grant runway plus UT Southwestern IP de-risk early development; APC-mutant CRC is a large biomarker-defined indication with clear regulatory path; TASIN platform provides optionality across multiple oncology and non-oncology indications.
Bear case: Founder-CEO concentration (Neil Thapar holds Co-Founder plus Board Chair plus CEO plus CSO simultaneously — governance flag); zero institutional biotech VC on cap table in 9 years post-founding suggests prior fundraising friction; reliance on Reg CF crowdfunding in 2026 reinforces this concern. Operationally lean (3 employees) means clinical execution risk is concentrated.
Barricade Therapeutics is a clinical-stage oncology company developing BT-1501, a once-daily oral small-molecule inhibitor of Emopamil Binding Protein (EBP) for advanced colorectal cancer driven by APC mutations (present in approximately 80% of CRC tumors).
Rather than directly targeting Wnt/beta-catenin signaling, BT-1501 exploits synthetic lethality by disrupting sterol-processing pathways APC-mutant cells depend upon, triggering apoptosis selectively in cancer cells. The asset is licensed from UT Southwestern's TASIN platform; preclinical data show 63-74% tumor growth inhibition in advanced CRC animal models. IND filing targeted Q2 2025 with Phase 1 initiation H2 2026.
Global colorectal cancer therapeutic market is approximately $13B today, projected to reach $20B by 2030 per company materials. APC mutations are present in approximately 80% of CRC patients, defining a large biomarker-selected addressable population.
Current standard of care for advanced CRC (chemotherapy combinations, anti-EGFR/anti-VEGF antibodies, KRAS-G12C inhibitors for the small mutated subset) leaves significant unmet need for the APC-mutant majority. A successful first-in-class oral targeted therapy could capture substantial share if Phase 1 efficacy translates.
Strong non-dilutive funding base: $17M total in CPRIT grants ($3M Seed plus $14M Texas Therapeutics Company Award) with positive Pre-IND FDA feedback already received, enabling Barricade to advance toward first-in-human studies without burning early equity.
Genetically targeted indication (APC-mutant CRC, 80% of CRC patients) carries clear biomarker-defined patient selection — a regulatory and commercial advantage versus broad-spectrum CRC therapies. TASIN platform exclusivity from UT Southwestern provides defensible IP and a multi-asset pipeline runway (neuroblastoma, lymphoma, MS, FAP).
Tiny team (3 employees per aVenture 2026-05 snapshot) and pre-clinical asset means Barricade is years from commercial validation. The company has raised only approximately $5.9M in equity and is now running a $1.24M Reg CF StartEngine crowdfunding round in 2026 — a financing path typically used by companies unable to secure traditional Series A from biotech VCs.
IND timeline has slipped: Nov 2024 press release implied near-term IND, but invest-site (April 2026) now positions Phase 1 start in H2 2026. Single-asset clinical-stage risk concentration with no diversifying near-term programs.
